Company to Host Conference Call and Webcast
on March 13, 2024
LOS
ANGELES, March 6, 2024 /PRNewswire/ -- Aadi
Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company
focused on developing and commercializing precision therapies for
patients with mTOR pathway alterations, today announced that it
will host a conference call and live webcast on Wednesday,
March 13, 2024 at 8:30 am ET (5:30 am PT) to report fourth quarter and
full-year 2023 financial results and provide recent corporate
updates.
Conference Call Information
Participants may access a live webcast of the call on the
"Investors & News" page of the Aadi
Bioscience website at aadibio.com. To participate via
telephone, please register in advance here: Conference
Registration (vevent.com). Upon registration, all telephone
participants will receive a confirmation email detailing how to
join the conference call, including the dial-in number along with a
unique passcode and registrant ID that can be used to access the
call. A replay of the conference call and webcast will be archived
on the website for at least 30 days.
About Aadi Bioscience, Inc.
Aadi is a commercial-stage biopharmaceutical company focused on
precision therapies for cancers to bring transformational therapies
to cancer patients with alterations in the mTOR pathway, a key
regulator of cell growth and cancer progression. Aadi received FDA
approval and has commercialized FYARRO® for the
treatment of adult patients with locally advanced unresectable or
metastatic malignant perivascular epithelioid cell tumor
(PEComa).
Aadi has also initiated PRECISION1, a Phase 2 tumor-agnostic
registration-intended trial in mTOR inhibitor-naïve malignant solid
tumors
harboring TSC1 or TSC2 inactivating
alterations. More information on the Company's development pipeline
is available on the Aadi website at www.aadibio.com and
connect with us on Twitter and LinkedIn.
Contact:
IR@aadibio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-report-fourth-quarter-and-full-year-2023-results-and-corporate-update-302078967.html
SOURCE Aadi Bioscience